8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Apr 16, 2026·SEC
Altimmune, Inc.(ALT)Earnings, Financials & Key Ratios
ALT•NASDAQ
Price updated Jun 19, 2026
AboutAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Show more
- Revenue$41K+105.0%
- EBITDA-$94M+8.3%
- Net Income-$88M+7.3%
- EPS (Diluted)-1.00+25.4%
- Gross Margin100%
- EBITDA Margin-230187.8%+55.3%
- Operating Margin-230460.98%+55.3%
- Net Margin-214860.98%+54.8%
- ROE-50.57%+15.5%
ALT Key Insights
Altimmune, Inc. (ALT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Profits declining 12.4% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Sales declining 65.3% over 5 years
- ✗Shares diluted 24.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ALT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALT Price & Volume
Altimmune, Inc. (ALT) stock price & volume — 10-year historical chart
Loading chart...
ALT Growth Metrics
Altimmune, Inc. (ALT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-42.64%
5 Years-65.33%
3 Years-
TTM80%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.19%
Return on Capital
10 Years-60.14%
5 Years-50.01%
3 Years-53.48%
Last Year-47.99%
ALT Recent Earnings
Altimmune, Inc. (ALT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (100%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.18+28.0%
$0.25
Rev
—
$1,429
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.27-8.0%
$0.25
Rev
$26,000+4576.3%
$556
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.21+27.6%
$0.29
Rev
$5,000+792.9%
$560
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.27+15.6%
$0.32
Rev
$5,000+249.9%
$1,429
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.18vs $0.25+28.0% | —vs $1,429 |
| Q2 2026 | Mar 5, 2026 | $0.27vs $0.25-8.0% | $26,000vs $556+4576.3% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.29+27.6% | $5,000vs $560+792.9% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.32+15.6% | $5,000vs $1,429+249.9% |
Based on last 12 quarters of dataView full earnings history →
ALT Peer Comparison
Altimmune, Inc. (ALT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 GPCR | 2.56B | 44.51 | -18.55 | -15.14% | 0.00 | |||
 ELVN | 2.75B | 45.10 | -24.64 | -21.04% | 0.00 | |||
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare ALT vs Peers
Altimmune, Inc. (ALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALT Income Statement
Altimmune, Inc. (ALT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 41.5K | 10.33M | 5.8M | 8.19M | 4.41M | -68K | 426K | 20K | 41K | 36K |
Revenue Growth % | -99.21% | 24792.58% | -43.85% | 41.09% | -46.12% | -101.54% | 726.47% | -95.31% | 105% | 80% |
Cost of Goods Sold | 18.41M | 18.46M | 0 | 33.51M | 0 | 0 | 0 | 0 | 0 | 14.98M |
COGS % of Revenue | 44349.39% | 178.68% | - | 409.4% | - | - | - | - | - | - |
Gross Profit | -18.36M▲ 0% | -8.13M▲ 55.7% | 5.8M▲ 171.4% | -25.32M▼ 536.5% | 4.41M▲ 117.4% | -68K▼ 101.5% | 426K▲ 726.5% | 20K▼ 95.3% | 41K▲ 105.0% | -14.95M▲ 0% |
Gross Margin % | -44249.39% | -78.68% | 100% | -309.4% | 100% | 100% | 100% | 100% | 100% | -41519.44% |
Gross Profit Growth % | -822.27% | 55.74% | 171.37% | -536.52% | 117.41% | -101.54% | 726.47% | -95.31% | 105% | - |
Operating Expenses | 16.17M | 28.22M | 27.27M | 29.47M | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M | 81.97M |
OpEx % of Revenue | 38953.97% | 273.2% | 470% | 360.1% | 2297.6% | -128929.41% | 22618.54% | 515960% | 230560.98% | - |
Selling, General & Admin | 8.46M | 9.77M | 8.5M | 13.21M | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M | 30.16M |
SG&A % of Revenue | 20378.18% | 94.53% | 146.53% | 161.39% | 349.5% | -25197.06% | 4257.51% | 104830% | 68531.71% | - |
Research & Development | 18.41M | 18.46M | 17.77M | 49.77M | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M | 66.77M |
R&D % of Revenue | 44349.39% | 178.68% | 306.23% | 608.11% | 1690.27% | -103732.35% | 15445.77% | 411130% | 162029.27% | - |
Other Operating Expenses | 5.67K | 277.89K | 1M | -33.51M | 11.37M | 0 | 12.42M | 0 | 0 | -1000K |
Operating Income | -52.05M▲ 0% | -42.83M▲ 17.7% | -21.46M▲ 49.9% | -54.8M▼ 155.3% | -96.91M▼ 76.9% | -87.74M▲ 9.5% | -95.93M▼ 9.3% | -103.17M▼ 7.6% | -94.49M▲ 8.4% | -96.92M▲ 0% |
Operating Margin % | -125401.2% | -414.61% | -370% | -669.5% | -2197.6% | 129029.41% | -22518.54% | -515860% | -230460.98% | -269216.67% |
Operating Income Growth % | -362.04% | 17.7% | 49.89% | -155.29% | -76.85% | 9.47% | -9.33% | -7.55% | 8.42% | - |
EBITDA | -51.91M | -42.53M | -21.08M | -54.37M | -96.36M | -87.25M | -95.45M | -102.93M | -94.38M | -96.81M |
EBITDA Margin % | -125066.24% | -411.69% | -363.32% | -664.26% | -2185.1% | 128304.41% | -22406.57% | -514670% | -230187.8% | -268922.22% |
EBITDA Growth % | -366.41% | 18.06% | 50.44% | -157.95% | -77.24% | 9.46% | -9.4% | -7.84% | 8.31% | 1.25% |
D&A (Non-Cash Add-back) | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K | 112K | 106K |
EBIT | -51.9M | -45.02M | -20.58M | -38.53M | -97.08M | -84.9M | -88.41M | -95.05M | -87.14M | -93.54M |
Net Interest Income | -114.56K | -70.49K | 841.16K | 313.09K | 198K | 2.86M | 7.32M | 8.06M | 5.91M | 6.19M |
Interest Income | 47.58K | 226.6K | 843.41K | 322.51K | 203K | 2.87M | 7.35M | 8.07M | 7.54M | 8.9M |
Interest Expense | 162.14K | 297.09K | 2.24K | 9.42K | 5K | 8K | 35K | 9K | 1.64M | 2.7M |
Other Income/Expense | -18.51K | -2.49M | 886.3K | 11.17M | -176K | 2.83M | 7.48M | 8.11M | 5.71M | 5.84M |
Pretax Income | -52.06M▲ 0% | -45.32M▲ 13.0% | -20.58M▲ 54.6% | -43.63M▼ 112.0% | -97.09M▼ 122.5% | -84.91M▲ 12.5% | -88.45M▼ 4.2% | -95.06M▼ 7.5% | -88.77M▲ 6.6% | -91.08M▲ 0% |
Pretax Margin % | -125445.79% | -438.68% | -354.72% | -533.02% | -2201.59% | 124867.65% | -20762.21% | -475295% | -216521.95% | -253002.78% |
Income Tax | -5.64M | -6.15M | -58.5K | 5.42M | 0 | -197K | 0 | 0 | -681K | 0 |
Effective Tax Rate % | 10.83% | 13.57% | 0.28% | -12.42% | 0% | 0.23% | 0% | 0% | 0.77% | 0% |
Net Income | -46.43M▲ 0% | -39.17M▲ 15.6% | -20.52M▲ 47.6% | -49.04M▼ 139.0% | -97.09M▼ 98.0% | -84.71M▲ 12.7% | -88.45M▼ 4.4% | -95.06M▼ 7.5% | -88.09M▲ 7.3% | -91.08M▲ 0% |
Net Margin % | -111860.32% | -379.16% | -353.71% | -599.2% | -2201.59% | 124577.94% | -20762.21% | -475295% | -214860.98% | -253002.78% |
Net Income Growth % | -123.95% | 15.63% | 47.61% | -139.01% | -97.96% | 12.75% | -4.41% | -7.48% | 7.33% | -0.93% |
Net Income (Continuing) | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M | -88.09M | -91.08M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -108.77▲ 0% | -13.98▲ 87.1% | -1.56▲ 88.8% | -1.91▼ 22.4% | -2.35▼ 23.0% | -1.81▲ 23.0% | -1.66▲ 8.3% | -1.34▲ 19.3% | -1.00▲ 25.4% | -0.73▲ 0% |
EPS Growth % | -118.41% | 87.15% | 88.84% | -22.44% | -23.04% | 22.98% | 8.29% | 19.28% | 25.37% | 26.19% |
EPS (Basic) | -108.77 | -13.98 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 | - |
Diluted Shares Outstanding | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M | 88.1M | 124.46M |
Basic Shares Outstanding | 426.83K | 2.8M | 13.12M | 25.64M | 41.28M | 46.93M | 53.25M | 71M | 88.1M | 124.46M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ALT Balance Sheet
Altimmune, Inc. (ALT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 23.47M | 39.37M | 39.39M | 230.26M | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M | 334.68M |
Cash & Short-Term Investments | 8.77M | 33.72M | 37.24M | 215.92M | 190.3M | 184.88M | 197.81M | 131.89M | 273.46M | 331.54M |
Cash Only | 8.77M | 33.72M | 8.96M | 115.92M | 190.3M | 111.1M | 135.12M | 36.93M | 43.76M | 97.6M |
Short-Term Investments | 0 | 0 | 28.28M | 100.01M | 0 | 73.78M | 62.7M | 94.97M | 229.7M | 233.94M |
Accounts Receivable | 10.17M | 4.47M | 1.65M | 12.37M | 5.84M | 2.54M | 4.85M | 3.12M | 1.74M | 1.67M |
Days Sales Outstanding | 89.42K | 157.96 | 103.83 | 551.76 | 483.27 | -13.64K | 4.16K | 56.89K | 15.46K | 9.9K |
Inventory | 3.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 70.08 | - | - | - | - | - | - | - | - | - |
Other Current Assets | 3.53M | 634.42K | 34.17K | 34.17K | 33.31K | 5.39M | 6.96M | 2.25M | 3M | 1.47M |
Total Non-Current Assets | 39.56M | 15.38M | 14.66M | 14.86M | 14.74M | 14.12M | 1.01M | 2.05M | 1.74M | 954K |
Property, Plant & Equipment | 603.15K | 1.34M | 1.8M | 1.96M | 1.45M | 1.08M | 651K | 413K | 312K | 208K |
Fixed Asset Turnover | 0.07x | 7.69x | 3.22x | 4.17x | 3.05x | -0.06x | 0.65x | 0.05x | 0.13x | 0.05x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 38.72M | 13.85M | 12.73M | 12.82M | 12.42M | 12.42M | 0 | 0 | 0 | 0 |
Long-Term Investments | -5.94B | -58.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 238.92K | 183.68K | 128.55K | 73.41K | 872K | 615K | 363K | 1.64M | 1.43M | 746K |
Total Assets | 63.03M▲ 0% | 54.75M▼ 13.1% | 54.06M▼ 1.3% | 245.12M▲ 353.4% | 218.87M▼ 10.7% | 206.93M▼ 5.5% | 210.64M▲ 1.8% | 139.31M▼ 33.9% | 279.93M▲ 100.9% | 335.63M▲ 0% |
Asset Turnover | 0.00x | 0.19x | 0.11x | 0.03x | 0.02x | -0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
Asset Growth % | -71.95% | -13.14% | -1.26% | 353.43% | -10.71% | -5.45% | 1.79% | -33.87% | 100.95% | 271.91% |
Total Current Liabilities | 3.84M | 4.53M | 3.92M | 12.02M | 18.28M | 17.05M | 12.14M | 10.47M | 15M | 11.32M |
Accounts Payable | 129.07K | 372.86K | 18.23K | 612.29K | 2.03M | 4.8M | 2.07M | 211K | 2.72M | 1.53M |
Days Payables Outstanding | 2.56 | 7.37 | - | 6.67 | - | - | - | - | - | 60.31 |
Short-Term Debt | 49.7K | 71.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 19.75K | 19.75K | 61.56K | 19.75K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.9M | 2.81M | 0 | 8.68M | 6.09M | 0 | 0 | 0 | 0 | 0 |
Current Ratio | 6.11x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x | 18.55x | 29.56x |
Quick Ratio | 5.19x | 8.70x | 10.04x | 19.16x | 11.17x | 11.31x | 17.26x | 13.11x | 18.55x | 29.56x |
Cash Conversion Cycle | 89.49K | - | - | - | - | - | - | - | - | 9.84K |
Total Non-Current Liabilities | 10.51M | 1.91M | 4.61M | 7.22M | 1.45M | 4.58M | 4.4M | 5.33M | 40.04M | 40.32M |
Long-Term Debt | 599.93K | 501.17K | 0 | 0 | 0 | 0 | 0 | 0 | 34.29M | 34.51M |
Capital Lease Obligations | 0 | 0 | 1.48M | 1.47M | 1.12M | 672K | 175K | 1.4M | 1.15M | 4.71M |
Deferred Tax Liabilities | 5.94M | 58.5K | 0 | -250K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.81M | 1.35M | 2.88M | 5.75M | 330K | 3.91M | 4.22M | 3.93M | 4.45M | 4.59M |
Total Liabilities | 14.35M | 6.44M | 8.54M | 19.24M | 19.73M | 21.64M | 16.54M | 15.8M | 55.04M | 51.64M |
Total Debt | 49.7K | 572.77K | 1.74M | 1.82M | 1.53M | 1.12M | 671K | 1.68M | 35.69M | 35.85M |
Net Debt | -8.72M | -33.15M | -7.22M | -114.09M | -188.77M | -109.97M | -134.45M | -35.24M | -8.07M | -61.75M |
Debt / Equity | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.16x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.37x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.64x |
Interest Coverage | -320.11x | -151.55x | -9169.51x | -4090.20x | -19417.00x | -10612.75x | -2526.06x | -10561.11x | -53.26x | -34.61x |
Total Equity | 48.68M▲ 0% | 48.31M▼ 0.7% | 45.52M▼ 5.8% | 225.88M▲ 396.2% | 199.13M▼ 11.8% | 185.29M▼ 7.0% | 194.1M▲ 4.8% | 123.51M▼ 36.4% | 224.89M▲ 82.1% | 283.99M▲ 0% |
Equity Growth % | 150.15% | -0.75% | -5.78% | 396.21% | -11.84% | -6.95% | 4.75% | -36.37% | 82.09% | 226.8% |
Book Value per Share | 114.04 | 17.24 | 3.47 | 8.81 | 4.82 | 3.95 | 3.65 | 1.74 | 2.55 | 2.28 |
Total Shareholders' Equity | 48.68M | 48.31M | 45.52M | 225.88M | 199.13M | 185.29M | 194.1M | 123.51M | 224.89M | 283.99M |
Common Stock | 1.81K | 876 | 1.51K | 3.7K | 4K | 5K | 7K | 7K | 11K | 13K |
Retained Earnings | -77.68M | -116.86M | -137.38M | -186.42M | -293.17M | -377.88M | -466.33M | -561.39M | -649.48M | -672.05M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -4.58M | -5.04M | -5.02M | -5.04M | -5.04M | -5.23M | -5M | -4.97M | -4.93M | -5.22M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALT Cash Flow Statement
Altimmune, Inc. (ALT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.21M | -9.39M | -9.6M | -34.31M | -78.24M | -62.59M | -75.81M | -79.85M | -67.53M | -71.94M |
Operating CF Margin % | -48705.1% | -90.88% | -165.51% | -419.13% | -1774.1% | 92038.24% | -17795.77% | -399240% | -164719.51% | - |
Operating CF Growth % | -110.03% | 53.55% | -2.27% | -257.28% | -128.06% | 20.01% | -21.13% | -5.33% | 15.42% | 16.79% |
Net Income | -46.43M | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M | -88.09M | -91.08M |
Depreciation & Amortization | 139.02K | 302.37K | 387.32K | 428.88K | 551K | 493K | 477K | 238K | 112K | 106K |
Stock-Based Compensation | 1.44M | 773.25K | 0 | 2.58M | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M | 8.49M |
Deferred Taxes | -2.62B | -6.15M | -58.5K | 0 | 0 | 0 | 0 | 0 | -681K | 0 |
Other Non-Cash Items | 2.65B | 27.88M | 8.77M | 16.25M | 13.03M | -578K | 9.79M | -3.9M | -1.7M | 5.86M |
Working Capital Changes | -11.31M | 6.98M | 1.82M | -4.51M | -251K | 14.11M | -8.27M | 4.48M | 6.75M | 4.69M |
Change in Receivables | -1.95M | 344.3K | 2.82M | -10.72M | 6.53M | 3.3M | -2.31M | 1.74M | 2.06M | 799K |
Change in Inventory | -4.12M | 5.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -2.62M | 243.06K | -354.63K | 594.06K | 1.42M | 2.77M | -2.73M | -1.86M | 2.51M | 453K |
Cash from Investing | 13.73M | -1M | -28.29M | -72.23M | 87.52M | -73.4M | 13.73M | -28.39M | -132.47M | -131.06M |
Capital Expenditures | -166.33K | -1.02M | -29K | -203.96K | -12.12M | -126K | -47K | 0 | -11K | -32K |
CapEx % of Revenue | 400.76% | 9.83% | 0.5% | 2.49% | 274.76% | -185.29% | 11.03% | - | 26.83% | 88.89% |
Acquisitions | 13.68M | 14.49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 207.63K | 14.49K | 0 | -138.46K | -195K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 15.84M | 32.49M | 12.53M | 213.49M | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M | 251.49M |
Debt Issued (Net) | 2.81M | -1.55M | -292K | 0 | 0 | 0 | 0 | 0 | 33.92M | 34.25M |
Equity Issued (Net) | 13.02M | 35.02M | 12.7M | 172.32M | 65.04M | 56.35M | 86.6M | 9.99M | 173.63M | 217.97M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -2.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 16.45K | -977.1K | 125K | 41.17M | 58K | 434K | -496K | 50K | -709K | -717K |
Net Change in Cash | 9.43M▲ 0% | 22.05M▲ 133.9% | -25.36M▼ 215.0% | 106.96M▲ 521.8% | 74.38M▼ 30.5% | -79.2M▼ 206.5% | 24.03M▲ 130.3% | -98.19M▼ 508.7% | 6.83M▲ 107.0% | 48.5M▲ 0% |
Free Cash Flow | -20.38M▲ 0% | -10.4M▲ 48.9% | -9.6M▲ 7.7% | -34.65M▼ 260.8% | -90.55M▼ 161.3% | -62.71M▲ 30.7% | -75.86M▼ 21.0% | -79.85M▼ 5.3% | -67.55M▲ 15.4% | -71.97M▲ 0% |
FCF Margin % | -49105.86% | -100.71% | -165.53% | -423.31% | -2053.29% | 92223.53% | -17806.81% | -399240% | -164746.34% | -199908.33% |
FCF Growth % | -110.12% | 48.95% | 7.7% | -260.8% | -161.34% | 30.74% | -20.96% | -5.26% | 15.41% | 10.41% |
FCF per Share | -47.75 | -3.71 | -0.73 | -1.35 | -2.19 | -1.34 | -1.42 | -1.12 | -0.77 | -0.58 |
FCF Conversion (FCF/Net Income) | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x | 0.77x | 0.79x |
Interest Paid | 0 | 0 | 0 | 1.79K | 0 | 0 | 0 | 0 | 0 | 381K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALT Key Ratios
Altimmune, Inc. (ALT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -136.27% | -80.77% | -43.74% | -36.14% | -45.69% | -44.07% | -46.63% | -59.86% | -50.57% | -42.57% |
Return on Invested Capital (ROIC) | -97.69% | -116.56% | -60.22% | -54.77% | -119.01% | -153.59% | -106.61% | -104.63% | -46.46% | -50.7% |
Gross Margin | -44249.39% | -78.68% | 100% | -309.4% | 100% | 100% | 100% | 100% | 100% | -41519.44% |
Net Margin | -111860.32% | -379.16% | -353.71% | -599.2% | -2201.59% | 124577.94% | -20762.21% | -475295% | -214860.98% | -253002.78% |
Debt / Equity | 0.00x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.16x | 0.13x |
Interest Coverage | -320.11x | -151.55x | -9169.51x | -4090.20x | -19417.00x | -10612.75x | -2526.06x | -10561.11x | -53.26x | -34.61x |
FCF Conversion | 0.44x | 0.24x | 0.47x | 0.70x | 0.81x | 0.74x | 0.86x | 0.84x | 0.77x | 0.79x |
Revenue Growth | -99.21% | 24792.58% | -43.85% | 41.09% | -46.12% | -101.54% | 726.47% | -95.31% | 105% | 80% |
Related:ALT Dividend History·ALT Revenue History·ALT Price History·ALT P/E History·ALT Financial Ratios·ALT Institutional Holders
ALT SEC Filings & Documents
Altimmune, Inc. (ALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALT Frequently Asked Questions
Altimmune, Inc. (ALT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Altimmune, Inc. (ALT) reported $0.0M in revenue for fiscal year 2025. This represents a 94% decrease from $0.6M in 2005.
Altimmune, Inc. (ALT) grew revenue by 105.0% over the past year. This is strong growth.
Altimmune, Inc. (ALT) reported a net loss of $91.1M for fiscal year 2025.
Dividend & Returns
Altimmune, Inc. (ALT) has a return on equity (ROE) of -50.6%. Negative ROE indicates the company is unprofitable.
Altimmune, Inc. (ALT) had negative free cash flow of $72.0M in fiscal year 2025, likely due to heavy capital investments.